W
Warburg Pincus
Acquirer counsel
Kirkland & Ellis
L · V · M
Laurent Victor-MichelPartner
Louis GossetPartner
12 lawyers involved
Rainmaker
Loading page...
Willkie advises Sebia on $6.2 billion sale to Warburg Pincus
Deal Overview
- Value
- $6.2bn
- Deal type
- M&A
- Structure
- Data in progress
- Status
- Data in progress
Advisors
ACQUIRER
Kirkland & Ellis Overview
- Warburg Pincus is entering exclusive negotiations to buy into Sebia, which the announcement describes as a global leader in specialty diagnostics.
- The transaction is structured as a potential acquisition by Warburg Pincus of a significant minority stake in Sebia.
- Signing has moved into exclusive negotiations, and completion is conditioned on employee consultation processes and customary regulatory approvals, with closing expected no earlier than Q1 2026.
S
Sebia
Seller counsel
Willkie Farr & Gallagher
Cédric HajagePartner
Florent MazeronCorporate/Private Equity Partner, Paris
Julien Bourmaud-DantoMainstream Corporate Partner, Paris
11 lawyers involved
Willkie Farr & Gallagher Overview
- Sebia is a global in vitro diagnostics company focused on equipment and reagents used to screen and monitor diseases.
- Warburg Pincus entered exclusive negotiations to acquire a significant minority stake in Sebia, with the transaction structured so CVC also reinvests rather than exiting completely.
- After closing, CVC funds, La Caisse and Tethys Invest are expected to remain significant investors in Sebia alongside Warburg Pincus.